Latest Convertible Notes News

Jade Gas Holdings has completed its appraisal program at the Tavan Tolgoi coal bed methane project, preparing to lodge its maiden gas reserve booking and advance development plans backed by fresh capital.

QPM Energy has secured critical approvals and financing milestones for its 112MW Isaac Power Station, alongside a significant upgrade to its Moranbah Gas Project reserves, positioning it as a key energy supplier in Queensland.

Peak Processing reported its first positive EBITDA month in March 2026, driven by operational efficiencies and strong production growth. The company upgraded its Q4 production forecast and expanded key customer contracts, signaling a turning point after a challenging period.

Syrah Resources delivered a record 24kt graphite production at Balama and secured US$72 million in equity to support medium-term ramp-up and Vidalia commercialisation, navigating a complex US trade environment.

Enlitic delivered its strongest quarter yet with A$5.1 million in contracts, including significant agreements with Penn Medicine, St. Jude Children’s Research Hospital, and Parkland Health, while improving cash flow and advancing its AI-powered Ensight platform.

Arafura Rare Earths has locked in binding cornerstone equity agreements worth approximately A$230 million, bolstering its path to a final investment decision for the Nolans Project. The company also acquired critical camp infrastructure and is progressing technology development and offtake negotiations amid supportive government frameworks.

CONNEQT Health’s Pulse device sales surged to a $7 million annualised run-rate despite a temporary supply hiccup, while the company manages a tight cash runway supported by new R&D loans and related-party funding.

Noble Helium has secured $12 million in a two-tranche placement to advance its North Rukwa helium project in Tanzania, positioning itself as a key player amid a global helium supply disruption caused by Middle East conflicts.

AuKing Mining has bolstered its project portfolio with the acquisition of a Tasmanian tin and silver licence and the Malawi-based Tundulu Rare Earths Project, supported by $5 million in recent equity placements.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

HITIQ Limited's March quarter saw a remarkable 223% jump in sales to $294k, driven by the nationwide rollout of its PROTEQT™ concussion management system and initial international sales. The company bolstered its governance and advisory ranks while managing funding to support its commercial push.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.